Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14862307 | 0.96 | IDO1 (0.36) | IDO1TDO2ALOX5 | |
| SCHEMBL14873238 | 0.96 | IDO1 (0.36) | IDO1TDO2ALOX5 | |
| Hydrochloric Acid SCHEMBL15400532 | 0.94 | IDO1 (0.39) | IDO1TDO2ALOX5 | |
| SCHEMBL16463242 | 0.92 | IDO1 (0.38) | IDO1TDO2ALOX5 | |
| SCHEMBL2551770 | 0.92 | IDO1 (0.38) | IDO1TDO2ALOX5 | |
| SCHEMBL18034384 | 0.81 | IDO1 (0.42) | IDO1TDO2ALOX5 | |
| SCHEMBL15550386 | 0.79 | IDO1 (0.44) | IDO1TDO2 | |
| SCHEMBL1308728 | 0.76 | IDO1 (0.38) | IDO1TDO2ALOX5 | |
| SCHEMBL22978807 | 0.73 | SLC6A2 (0.37) | IDO1TDO2ALOX5 | |
| SCHEMBL3962571 | 0.72 | LMNA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
| WO-2011123937-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011123937-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | IDO1 436/4885TDO2 1066/4885ALOX5 1795/4885 |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | IDO1 4247/4885TDO2 4657/4885ALOX5 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.